83.81
price down icon1.16%   -0.94
after-market After Hours: 83.68 -0.13 -0.16%
loading
Incyte Corp stock is traded at $83.81, with a volume of 1.29M. It is down -1.16% in the last 24 hours and down -2.88% over the past month. Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$84.75
Open:
$85.01
24h Volume:
1.29M
Relative Volume:
0.76
Market Cap:
$16.36B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
19.05
EPS:
4.3988
Net Cash Flow:
$945.58M
1W Performance:
-3.55%
1M Performance:
-2.88%
6M Performance:
+51.84%
1Y Performance:
+28.15%
1-Day Range:
Value
$83.06
$85.19
1-Week Range:
Value
$83.06
$88.30
52-Week Range:
Value
$53.56
$88.66

Incyte Corp Stock (INCY) Company Profile

Name
Name
Incyte Corp
Name
Phone
(302) 498-6700
Name
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Employee
2,617
Name
Twitter
@Incyte
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
INCY's Discussions on Twitter

Compare INCY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
INCY
Incyte Corp
83.80 16.55B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.91 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
460.52 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.59 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
797.22 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.27 36.88B 4.56B -176.77M 225.30M -1.7177

Incyte Corp Stock (INCY) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-08-25 Downgrade Oppenheimer Outperform → Perform
Aug-06-25 Upgrade Wells Fargo Equal Weight → Overweight
Aug-01-25 Initiated Barclays Overweight
Jun-16-25 Upgrade Stifel Hold → Buy
Mar-18-25 Downgrade Guggenheim Buy → Neutral
Mar-18-25 Downgrade William Blair Outperform → Mkt Perform
Dec-17-24 Initiated UBS Neutral
Oct-29-24 Upgrade BofA Securities Neutral → Buy
Oct-01-24 Initiated Wolfe Research Outperform
Sep-18-24 Downgrade Truist Buy → Hold
Jul-02-24 Downgrade BMO Capital Markets Market Perform → Underperform
May-23-24 Initiated Deutsche Bank Hold
Apr-23-24 Initiated Cantor Fitzgerald Neutral
Feb-23-24 Initiated Jefferies Buy
Feb-14-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-13-23 Upgrade Leerink Partners Market Perform → Outperform
Dec-04-23 Upgrade Guggenheim Neutral → Buy
Nov-21-23 Downgrade Goldman Buy → Neutral
Jul-25-23 Initiated Citigroup Buy
May-04-23 Downgrade BofA Securities Buy → Neutral
Apr-10-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-24-23 Upgrade SVB Securities Underperform → Market Perform
Jan-31-23 Initiated Piper Sandler Overweight
Aug-03-22 Downgrade Evercore ISI Outperform → In-line
Aug-03-22 Downgrade Guggenheim Buy → Neutral
Jul-28-22 Initiated Wells Fargo Equal Weight
Feb-09-22 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-18-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-19-21 Initiated BMO Capital Markets Market Perform
Jul-20-21 Upgrade The Benchmark Company Hold → Buy
Feb-10-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jan-07-21 Initiated Truist Buy
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jun-16-20 Initiated The Benchmark Company Hold
May-06-20 Downgrade JP Morgan Overweight → Neutral
Apr-29-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-24-20 Resumed William Blair Outperform
Mar-13-20 Upgrade BofA/Merrill Neutral → Buy
Feb-04-20 Resumed BofA/Merrill Neutral
Jan-03-20 Reiterated BMO Capital Markets Market Perform
Jan-03-20 Downgrade Mizuho Buy → Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Oct-03-19 Initiated Mizuho Buy
Sep-12-19 Initiated BMO Capital Markets Market Perform
Sep-05-19 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Sep-05-19 Resumed Morgan Stanley Equal-Weight
Sep-05-19 Upgrade Oppenheimer Perform → Outperform
May-21-19 Initiated Credit Suisse Neutral
May-03-19 Downgrade Barclays Overweight → Equal Weight
Apr-11-19 Initiated Stifel Hold
Apr-03-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-24-19 Upgrade William Blair Mkt Perform → Outperform
View All

Incyte Corp Stock (INCY) Latest News

pulisher
10:18 AM

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock - MarketBeat

10:18 AM
pulisher
Oct 09, 2025

What 14 Analyst Ratings Have To Say About Incyte - Benzinga

Oct 09, 2025
pulisher
Oct 09, 2025

Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360

Oct 09, 2025
pulisher
Oct 09, 2025

INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Can Incyte Corporation rally from current levels2025 Year in Review & Weekly Watchlist for Consistent Profits - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Incyte Corporation stock a safe buy before earnings2025 Technical Overview & Smart Investment Allocation Insights - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Incyte Faces Revenue Squeeze As Jakafi Patent Winds Down - Finimize

Oct 08, 2025
pulisher
Oct 08, 2025

Incyte to Report Third Quarter Financial Results - Business Wire

Oct 08, 2025
pulisher
Oct 08, 2025

Incyte stock rating downgraded to Perform by Oppenheimer - Investing.com

Oct 08, 2025
pulisher
Oct 07, 2025

Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Incyte Corporation (INCY) Appoints New Principal Financial Officer - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

How to use Fibonacci retracement on Incyte CorporationPortfolio Update Summary & Target Return Focused Stock Picks - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Grimes & Company Inc. Has $12.26 Million Position in Incyte Corporation $INCY - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Price action breakdown for Incyte CorporationJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Legacy Trust Cuts Holdings in Incyte Corporation $INCY - MarketBeat

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 05:30:49 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why Incyte Corporation (ICY) stock is favored by hedge funds2025 Stock Rankings & Community Consensus Stock Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How Incyte Corporation (ICY) stock reacts to stronger dollar2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Institutional scanner results for Incyte Corporation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner - MyChesCo

Oct 04, 2025
pulisher
Oct 04, 2025

Incyte Appoints Thomas Tray as Financial Officer - The Globe and Mail

Oct 04, 2025
pulisher
Oct 04, 2025

Impact Investors Inc Has $209,000 Stock Position in Incyte Corporation $INCY - MarketBeat

Oct 04, 2025
pulisher
Oct 04, 2025

Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat

Oct 04, 2025
pulisher
Oct 03, 2025

Will Incyte's (INCY) New Strategy Team and CALR Antibody Hopes Reshape Its Long-Term Story? - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Incyte appoints Thomas Tray as principal financial officer - StreetInsider

Oct 03, 2025
pulisher
Oct 03, 2025

Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN

Oct 03, 2025
pulisher
Oct 03, 2025

Incyte (INCY) Is Up 5.7% After FDA Pediatric Opzelura Approval and Leadership Updates Has the Bull Case Changed? - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition - MyChesCo

Oct 03, 2025
pulisher
Oct 03, 2025

Will Incyte Corporation stock outperform value stocksWeekly Gains Report & Community Consensus Trade Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Backtesting results for Incyte Corporation trading strategiesMarket Risk Summary & Community Consensus Picks - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Incyte Corporation stock hits 52-week high at 88.19 USD By Investing.com - Investing.com Australia

Oct 02, 2025
pulisher
Oct 02, 2025

FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis - MSN

Oct 02, 2025
pulisher
Oct 02, 2025

Incyte Corporation stock hits 52-week high at 88.19 USD - Investing.com

Oct 02, 2025
pulisher
Oct 02, 2025

Robeco Institutional Asset Management B.V. Has $162.51 Million Stock Position in Incyte Corporation $INCY - MarketBeat

Oct 02, 2025
pulisher
Oct 02, 2025

2 Reasons to Like INCY and 1 to Stay Skeptical - The Globe and Mail

Oct 02, 2025
pulisher
Oct 01, 2025

Lbp Am Sa Has $12.17 Million Stock Position in Incyte Corporation $INCY - MarketBeat

Oct 01, 2025
pulisher
Oct 01, 2025

Public Employees Retirement System of Ohio Buys 3,951 Shares of Incyte Corporation $INCY - MarketBeat

Oct 01, 2025
pulisher
Sep 30, 2025

Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat

Sep 30, 2025
pulisher
Sep 29, 2025

Will Incyte Corporation (ICY) stock see insider accumulationQuarterly Profit Report & AI Enhanced Market Trend Forecasts - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication - GlobeNewswire Inc.

Sep 28, 2025
pulisher
Sep 27, 2025

Candlestick signals on Incyte Corporation stock todayMarket Performance Recap & Breakout Confirmation Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance

Sep 27, 2025
pulisher
Sep 25, 2025

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN

Sep 25, 2025
pulisher
Sep 25, 2025

Jim Cramer Calls Incyte “Way Too Cheap” - Yahoo Finance

Sep 25, 2025
pulisher
Sep 25, 2025

Ruffer LLP Sells 9,988 Shares of Incyte Corporation $INCY - MarketBeat

Sep 25, 2025
pulisher
Sep 25, 2025

Incyte (INCY) Gets a Hold from RBC Capital - The Globe and Mail

Sep 25, 2025

Incyte Corp Stock (INCY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Incyte Corp Stock (INCY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Denton Sheila A.
EVP & General Counsel
Oct 03 '25
Sale
85.54
3,501
299,476
26,569
Denton Sheila A.
EVP & General Counsel
Oct 02 '25
Sale
87.65
599
52,502
33,200
$21.35
price down icon 5.78%
$31.82
price down icon 0.17%
$102.06
price down icon 2.38%
$162.22
price down icon 1.14%
biotechnology ONC
$320.27
price down icon 4.62%
Cap:     |  Volume (24h):